Proteins are central to disease biology and therapeutic intervention, yet system-wide, in situ proteomic profiling remains underutilized in early-stage drug discovery. Microscoop® Mint from Syncell addresses this gap with a high-resolution, imaging-guided sample preparation platform that enables unbiased, subcellular proteomic analysis across diverse tissue types. Unlike traditional methods, Microscoop Mint achieves precise isolation of structures as small as 350 nm, is compatible with fresh, frozen, and FFPE tissues, and operates in a hypothesis-free manner—empowering scientists to identify novel drug targets, track therapeutic mechanisms, and explore previously inaccessible protein landscapes.
Already applied in neuroscience and oncology, Microscoop Mint is helping researchers map protein composition in complex tissues and subcellular structures, including neurodegenerative lesions and tumor microenvironments. By combining microscopy-guided biotinylation with mass spectrometry, the platform provides highly specific datasets for drug discovery, biomarker identification, and translational research. Discover how Microscoop Mint can transform your proteomics workflow and accelerate target discovery—read the full article on Drug Discovery News here.
